72 results found.
Reapplying the brakes in out of control CLL cells
Chronic lymphocytic leukaemia typically responds well to chemotherapy and other treatments, but eventually these treatments can stop working. Dr Michie is investigating ways we can overcome this problem.
Monitoring the progression of aggressive blood cancers and finding new ways to stop them
Dr Andrejs Braun is studying a protein that he thinks may help to predict how aggressive certain types of blood cancer will be. They want to understand how and why this protein can influence the outcome of blood cancer.
Attacking the roots of AML
In some cases of AML, people can see their disease return. This is because some cells get left behind despite treatment. Professor Bertie Göttgens wants to understand more about this and find new ways to treat the disease.
How does leukaemia develop in babies?
Some babies develop leukaemia’s as a result of changes that happen before birth. Professor Katrin Ottersbach wants to understand more about these changes and why some babies see their cancer return despite treatment.
Developing a risk score for graft-versus host disease in stem cell transplants
Graft versus host disease is a dangerous complication of stem or bone marrow transplant. Professor Paul Moss wants to understand more about the disease so we predict who might develop it.
Zeroing in on a pathway that drives myeloma
Myeloma is a blood cancer of the plasma cells, which is difficult to treat. Professor Ulf Klein is studying a signalling pathway thought to be involved in the disease in the hope of being able to identify new treatment targets.
Mapping gene changes in ALL
A change in a gene called BCR-ABL can initiate the development of acute lymphoblastic leukaemia. However, other changes happen which cause the disease to develop fully. Dr Feldahn wants to understand more about this process.
Developing a new type of treatment for leukaemia
Despite the progress we’ve made, we still not able to cure everyone with leukaemia with the treatments we have. Prof Terence Rabbitts is developing a brand-new type of treatment which could provide a new option for people with leukaemia.
Developing more effective and safer treatments for childhood leukaemia
We need to continue to develop treatments for childhood acute lymphoblastic leukaemia (ALL). Prof Tariq Enver and his team are learning more about the biology of childhood ALL, and why it sometimes comes back after treatment. This work could ensure that everyone gets treatments tailored for them, to give them the best chance of a cure.
The Precision Medicine in Aggressive Lymphoma consortium
Standard treatments for diffuse large B-cell lymphoma (DLBCL) don’t work for everyone. Prof Johnson is leading a team of researchers from across UK to find better ways to categorise and diagnose DLBCL. This will help ensure everyone with DLBCL gets the right treatment for them.
Understanding the biology of aggressive DLBCL
We need to find new ways to treat diffuse large B-cell lymphoma (DLBCL). Prof Ming-Qing Du is studying changes in the DNA of an aggressive type of DLBCL. This could lead to new treatments to give people living with the disease a better chance of survival.
Studying how the immune system behaves in myeloma
We need to find better ways to treat myeloma. Prof Kwee Yong is studying how the immune system changes in myeloma and during its treatment. She hopes that this could help people with myeloma keep their cancer at bay for longer.
Repurposing drugs to treat acute myeloid leukaemia
We desperately need new treatments for acute myeloid leukaemia (AML). Dr Karen Keeshan is studying whether existing drugs for solid tumours could be used to treat AML. This could quickly provide a new option for people living with the disease.
Improving the lives of children with leukaemia through tailored treatment
While we know that multiple genetic changes can cause Leukaemia, it's hard to identify them without comparing lots of leukaemia DNA samples. Professor Christine Harrison's project collects and analyses genetic information from children with leukaemia to try and understand how to treat the disease.
The STELLAR trial: Finding new treatments for Richter’s syndrome
Richter’s syndrome is a complication of chronic lymphocytic leukaemia and is a condition very difficult to treat. In this trial, Dr Anna Schuh will add an additional drug to current treatment for Richter’s syndrome to see if this improves the outcome.
Professor Claire Harrison wants to trial a new drug in people who have MPN who are unable to receive standard chemotherapy.
This trial will look at a new treatment combination for people with a more advanced phase of CML who have limited treatment options left.
This trial is looking at treatment for children who have acute lymphoblastic leukaemia (ALL) or a type of non-Hodgkin lymphoma (NHL) called lymphoblastic lymphoma (LBL). The aim is to find a way to reduce the side effects of ALL and LBL treatment and reduce the risk of the cancer coming back.
There are a number of different treatments doctors use to treat people with chronic lymphocytic leukaemia (CLL). These methods are effective but can have serious side effects and may not be suitable for some people. Researchers hope that a new drug can be used to treat these people.
Researchers want to find out if a combination of drugs can help treat people with chronic lymphocytic leukaemia (CLL) that has come back after treatment as well as in people where treatment has stopped working.